

Creating the Healthiest Nation:

Improving Outcomes for Women with Ovarian Cancer

**Jeannette Jackson-Thompson, MSPH, PhD^{1,2,3},
Nancy Rold, BA, CTR^{1,2}
Chester L. Schmaltz, PhD^{1,2}
Saba Yemane, BS^{1,2}**

Affiliations:

1. Missouri Cancer Registry and Research Center (MCR-ARC)
2. University of Missouri-Columbia (MU), School of Medicine, Dept. of Health Management & Informatics
3. MU Informatics Institute, Columbia, Missouri

Let's talk about:

- How the **Missouri Cancer Registry and Research Center (MCR-ARC)** participated in a **3-state (MO, IO & KS) study to assess patterns of ovarian cancer care, treatment and survival in the Midwest.**

Background

- Ovarian cancer is the 11th most common cause of cancer but is the 5th leading cause of cancer-related death among US women.
- Unlike breast and cervical cancers, there are no recommended screening tests for ovarian cancer for women who are not at high risk of developing ovarian cancer.
- Less than 20% of ovarian cancers are detected at an early stage, when the 5-year survival rate is over 90%.
- Nearly 60% of ovarian cancers are detected at an advanced (distant) stage (30% survival rate).
- Studies have shown that involvement of a gynecologic oncologist (GO) leads to improved outcomes, possibly due to greater adherence by GOs to guidelines-based care.
- The Midwest region of the US has fewer GOs compared to other regions in the US.

Methods

- Missouri was one of three Midwest-region state central cancer registries (CCRs) recruited to participate in the study; the other two were Iowa and Kansas.
- A SAS program developed by the Centers for Disease Control and Prevention (CDC) was used to create a sample, using selection criteria and random sampling.

To obtain more complete information on treatment for a patterns of care study, carefully consider IT & data availability issues. Good relationships with reporting facility staff are helpful.



For more information, contact:

Jeannette Jackson-Thompson, MSPH, PhD
Director, Missouri Cancer Registry and Research Center
JacksonThompsonJ@health.Missouri.edu
573-882-7775, <http://mcr.umh.edu>



Scan the QR code for my contact info.

Methods (continued)

- Selection criteria included: Primary Site (Ovary, Fallopian Tube & Primary Peritoneal); Behavior (Malignant) Histology; Year of Diagnosis (2011-2012); Age at Diagnosis; First Primary; and Resident of the CCR state.
- A total of 1,055 Missouri cases met criteria.
- Missouri's quota for the study was 334 cases.
- A total of 52 hospitals (large, medium and small caseload) from all regions of the state were involved.
- Missouri's quota for the study was 334 cases.
- Additional data on treatment, Go involvement, etc., were collected (October 2017-July 2018).

Results

- CCRs collected a total of 1,003 incidence and 432 recurrence ovarian cancer cases, nearly 20% from rural or non-metropolitan areas.
- Missouri contributed 334 incidence cases from 52 hospitals.
- Information about GO involvement was easier to obtain than chemotherapy information.
- Dose was unknown for over 25% of cases.

Discussion

- CCRs were required to use diagnosis years selected by the funding agency.
- Unforeseen events led to a delay in the start of data collection.
- Many records had been archived.
- Some hospitals had upgraded their EHRs and records from the old HER system could not be obtained.
- Good relationships with reporting facility staff was a key to getting cases from all 52 hospitals.
- GO involvement was more widespread than anticipated.

Recommendation

- When choosing criteria for a patterns of care study, using more recent year(s) of diagnosis can provide more complete data and should be balanced against the utility of the outcome measures.



Poster adapted from the "Better Poster Presentation" template originally by Mike Morrison (version 14).

This project was conducted by CDC, Westat and the state cancer registries of Iowa, Kansas, and Missouri, and funded under CDC contract 200-2014-61258. The Iowa Cancer Registry is also funded in part with Federal funds from NIH/NCI contract HHSN2612018000121 and cancer center support grant NIH/NCI P30CA086862. The Kansas Cancer Registry is also funded by the Kansas Department of Health and Environment. The Missouri Cancer Registry core activities are supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (U58DP006299-01-03) and a Surveillance Contract between DHSS and the University of Missouri.

We would like to acknowledge the work of the other members of the Ovarian Cancer Treatment Study Group: Lisa L. Hunter, Charles F. Lynch, Michele M. West (Iowa Cancer Registry); Sue-Min Lai, Sarma Garimella, John Keighley, Li Huang (Kansas Cancer Registry); Wilhelmina Ross, Diane Ng, Maricarmen Traverso-Ortiz (Westat); Jennifer M. Wike (CDC contractor); Trevor D. Thompson, Sun Hee Rim, Angela Moore, Sherri L. Stewart (CDC).

We would like to thank Jeff Steffens, BS CTR, the MCR-ARC Quality Assurance staff and the staff of facilities throughout Missouri and other states' central cancer registries for their dedication and desire for continuous quality improvement and submitting their reportable cases to MCR-ARC.